SCHEDULE: Franklin Templeton Discloses Jade Biosciences Stake

Franklin Templeton, Inc. has reported beneficial ownership of 6.0% of Jade Biosciences, Inc. common stock as of September 30, 2026.

Summary

• Franklin Templeton, Inc. (FTI) has filed a Schedule 13G, indicating beneficial ownership of 3,807,236 shares of Jade Biosciences, Inc. common stock.
• This represents 6.0% of the class of securities.
• The filing is dated October 26, 2026, with the event requiring the filing occurring on September 30, 2026.
• The shares are held by various investment management subsidiaries of FTI, including Franklin Advisers, Inc., Franklin Mutual Advisers, LLC, and Fiduciary Trust International LLC.
• Charles B. Johnson and Rupert H. Johnson, Jr., principal shareholders of FTI, are also listed but disclaim beneficial ownership of these shares.
• FTI and its subsidiaries assert they are not a 'group' for the purposes of Rule 13d-5.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily a routine disclosure of beneficial ownership changes rather than a reflection of company performance or strategic shifts.

Positives

• Franklin Templeton's investment indicates confidence in Jade Biosciences, potentially signaling stability or future growth prospects.
• The clear disclosure provides transparency to the market regarding significant institutional ownership.

Negatives

• The filing does not provide any financial performance data or strategic updates for Jade Biosciences, limiting insight into the company's operational health.
• The disclaimers of beneficial ownership by Charles B. Johnson and Rupert H. Johnson, Jr., while standard for this type of filing, can add a layer of complexity in understanding ultimate control.

Risks

• The primary risk is that the filing is a routine disclosure and does not contain information about Jade Biosciences' operational performance or future prospects, leaving investors to seek that information elsewhere.
• Potential for future changes in Franklin Templeton's stake, which could impact Jade Biosciences' stock price.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Jade Biosciences' future performance.

Management Comments

• Franklin Templeton, Inc. (FTI) was renamed from Franklin Resources, Inc. effective August 17, 2026.
• The clients of the Investment Management Subsidiaries have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, the securities reported herein.
• FTI, the Principal Shareholders, and each of the Investment Management Subsidiaries believe that they are not a 'group' within the meaning of Rule 13d-5 under the Act and that they are not otherwise required to attribute to each other the beneficial ownership of the securities held by any of them.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like Franklin Templeton when their ownership stake in a public company crosses a certain threshold (typically 5%). This filing indicates a significant, but not controlling, stake in Jade Biosciences, placing Franklin Templeton among the larger institutional holders.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional investor's holdings, which may influence market perception.
• Management of Jade Biosciences: Awareness of Franklin Templeton's substantial stake may inform strategic discussions and investor relations efforts.

Next Steps

• Franklin Templeton will continue to monitor its investment in Jade Biosciences.
• Jade Biosciences will continue its business operations as disclosed in its other filings.

Key Dates

Keywords

beneficial ownership, Schedule 13G, institutional investor, investment management, Franklin Templeton, Jade Biosciences, common stock, equity holding